~ 30% of RA patients treated with ACTEMRA achieved a DAS28 remission at 6 months, regardless of concomitant treatment and prior therapy.
Phase III Clinical Trials
The efficacy of ACTEMRA in alleviating the signs and symptoms of rheumatoid arthritis (RA) was assessed in five randomised, double-blind, multicentre Phase III studies. The studies OPTION, TOWARD and LITHE investigated the efficacy and safety of tocilizumab in patients with inadequate response to one or more DMARDs (DMARD-IR). All studies enrolled patients ≥18 years of age with active RA diagnosed according to the American College of Rheumatology (ACR) criteria and who had at least eight tender and six swollen joints at baseline.
Detailed results of these trials can be found in the Efficacy and Safety and Tolerability sections of the website.
Reference:
ACTEMRA Product Information (HK), Current at August 2010
- © 2012 Roche Hong Kong Limited
This website contains information on products which is targeted to a wide range
of audiences and could contain product details or information otherwise not accessible or valid in
your country.
Please be aware that we do not take any responsibility for accessing such information which may
not comply with any legal process, regulation, registration or usage in the country of your origin.
Remark: This statement has been translated into Chinese. In case of inconsistency between the
English and Chinese versions, the English version shall prevail.